Who is a candidate for high-dose interleukin-2 therapy for kidney cancer?

High-dose interleukin-2 (IL-2) therapy is Food and Drug Administration (FDA)-approved and is considered standard treatment for patients with metastatic renal cell carcinoma.
Kidney cancer patients suitable for high-dose IL-2 treatment:
  • Must be diagnosed with metastatic kidney cancer (cancer that has spread to other parts of the body)
  • Must be out of bed more than 50 percent of the day
  • Have relatively normal function of heart, lungs, kidneys, and liver
  • Have brain metastases treated and stable
  • Should not take/use steroids or steroid-containing compounds

Continue Learning about Anti-HIV Agent

Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.